Education
About Us
Working with TipRanks
Follow Us
Invion (IVIXF)
OTHER OTC:IVIXF
IVIXF Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EST
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.05
Previous CloseN/A
Volume2.00
Average Volume (3M)0.00
Market Cap
$5.32M
Enterprise Value$7.17M
Total Cash (Recent Filing)$137.54K
Total Debt (Recent Filing)$627.68K
Price to Earnings (P/E)―
Beta-3.10
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding96,965,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market Cap1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.51
Enterprise Value/Ebitda-1.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Photosoft PlatformInvion’s Photosoft platform represents a durable product-development advantage: a platform approach can address multiple indications and attract partnerships or licensing. If preclinical progress translates to clinical proof, platform scalability supports long-term value creation across disease areas.
Low Leverage / No DebtA clean capital structure with no reported debt reduces insolvency and interest-service risk. For an R&D-stage biotech this increases strategic optionality to fund development via equity, partnerships, or milestone deals without near-term fixed financial obligations.
Lean Operating StructureA very small team implies low fixed overhead, allowing management to allocate limited cash disciplinedly to core R&D. This lean structure can extend runway between financings and keeps burn more controllable compared with larger peers during preclinical development.
Bears Say
No Revenue; Widening LossesThe absence of revenue paired with materially larger losses indicates the company is not yet generating commercial cash flows and is still consuming capital to advance programs. Persistent losses increase reliance on external funding and raise dilution and execution risk over the next 2–6 months.
Eroding Equity And AssetsSignificant year-over-year declines in equity and assets reflect cumulative losses that reduce the balance-sheet cushion. For a pre-revenue biotech this weakens financial flexibility, limits borrowing or partnership leverage, and raises solvency concerns if losses persist.
Negative Operating Cash FlowSustained negative operating cash flow and negative free cash flow mean the business must secure external capital to fund R&D and potential trials. Dependence on financings or deals increases dilution risk and can constrain the pace of development absent material operational improvements.
Invion News
IVIXF FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was $0.04 and its highest was $0.05 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is $5.32M.
When is Invion’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Invion’s earnings last quarter?
Currently, no data Available
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 96,965,320 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in IVIXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IVIXF Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
-74.92%
Trailing 12-Months
Asset Growth
-39.74%
Trailing 12-Months
Company Description
Invion
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---